WO2008065485A3 - Compositions pharmaceutiques stables composées d'un bloqueur des canaux calcium et d'un inhibiteur ace - Google Patents

Compositions pharmaceutiques stables composées d'un bloqueur des canaux calcium et d'un inhibiteur ace Download PDF

Info

Publication number
WO2008065485A3
WO2008065485A3 PCT/IB2007/003003 IB2007003003W WO2008065485A3 WO 2008065485 A3 WO2008065485 A3 WO 2008065485A3 IB 2007003003 W IB2007003003 W IB 2007003003W WO 2008065485 A3 WO2008065485 A3 WO 2008065485A3
Authority
WO
WIPO (PCT)
Prior art keywords
calcium channel
channel blocker
ace inhibitor
stable pharmaceutical
pharmaceutical compositions
Prior art date
Application number
PCT/IB2007/003003
Other languages
English (en)
Other versions
WO2008065485A2 (fr
Inventor
Nagaria Rahul Maheshchandra
Vaidya Abhay Anantrao
Achanta Srinivasa Ramac Murthy
Nadkarni Sunil Sadanand
Original Assignee
Torrent Pharmaceuticals Ltd
Nagaria Rahul Maheshchandra
Vaidya Abhay Anantrao
Achanta Srinivasa Ramac Murthy
Nadkarni Sunil Sadanand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/636,536 external-priority patent/US20080096863A1/en
Application filed by Torrent Pharmaceuticals Ltd, Nagaria Rahul Maheshchandra, Vaidya Abhay Anantrao, Achanta Srinivasa Ramac Murthy, Nadkarni Sunil Sadanand filed Critical Torrent Pharmaceuticals Ltd
Priority to BRPI0717974-0A2A priority Critical patent/BRPI0717974A2/pt
Publication of WO2008065485A2 publication Critical patent/WO2008065485A2/fr
Publication of WO2008065485A3 publication Critical patent/WO2008065485A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une compositions pharmaceutique stable composée d'une combinaison d'un bloqueur des canaux calcium et d'un inhibiteur ACE, les deux ingrédients actifs n'étant pas physiquement séparés et la composition possédant un pH supérieur à 6,0. L'invention se rapporte également à un procédé de préparation et à un procédé d'utilisation de ladite composition.
PCT/IB2007/003003 2006-10-19 2007-10-10 Compositions pharmaceutiques stables composées d'un bloqueur des canaux calcium et d'un inhibiteur ace WO2008065485A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI0717974-0A2A BRPI0717974A2 (pt) 2006-10-19 2007-10-10 Composições farmacêuticas estáveis de um bloqueador dos canais de cálcio e um inibidor de ace

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1732/MUM/2006 2006-10-19
IN1732MU2006 2006-10-19
US11/636,536 US20080096863A1 (en) 2006-10-19 2006-12-11 Stable pharmaceutical compositions of calcium channel blocker and an ACE inhibitor
US11/636,536 2006-12-11

Publications (2)

Publication Number Publication Date
WO2008065485A2 WO2008065485A2 (fr) 2008-06-05
WO2008065485A3 true WO2008065485A3 (fr) 2009-04-23

Family

ID=39468314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/003003 WO2008065485A2 (fr) 2006-10-19 2007-10-10 Compositions pharmaceutiques stables composées d'un bloqueur des canaux calcium et d'un inhibiteur ace

Country Status (1)

Country Link
WO (1) WO2008065485A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010026470A1 (fr) * 2008-09-04 2010-03-11 Aurobindo Pharma Limited Formes posologiques stables d’agents antihypertenseurs
WO2013121233A1 (fr) 2012-02-17 2013-08-22 Egis Gyógyszergyár Nyilvánosan Működö Részvénytársaság Formule pharmaceutique à stabilité améliorée
PL227900B1 (pl) 2012-11-15 2018-01-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
HUP1300496A2 (hu) 2013-08-16 2015-03-02 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Stabil kombinációs gyógyszerkészítmény
CN104000790A (zh) * 2014-04-28 2014-08-27 万特制药(海南)有限公司 拉西地平分散片及其制备方法
CN117538462B (zh) * 2024-01-10 2024-03-26 地奥集团成都药业股份有限公司 一种氨氯地平贝那普利胶囊有关物质的检测方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20116428U1 (de) * 2000-12-29 2002-01-10 Bioorg Bv Pharmazeutische Zusammensetzungen umfassend Amlodipinmaleat
WO2006085208A2 (fr) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Formes galeniques solides stables d'amlodipine et de benazepril
WO2006097943A2 (fr) * 2005-03-15 2006-09-21 Lupin Limited Compositions pharmaceutiques d'amlodipine et de benazepril.
WO2007040511A1 (fr) * 2005-09-28 2007-04-12 Teva Pharmaceutical Industries Ltd. Combinaisons stables de bésylate d'amlodipine et d'hydrochlorure de bénazépril

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20116428U1 (de) * 2000-12-29 2002-01-10 Bioorg Bv Pharmazeutische Zusammensetzungen umfassend Amlodipinmaleat
WO2006085208A2 (fr) * 2005-02-11 2006-08-17 Ranbaxy Laboratories Limited Formes galeniques solides stables d'amlodipine et de benazepril
WO2006097943A2 (fr) * 2005-03-15 2006-09-21 Lupin Limited Compositions pharmaceutiques d'amlodipine et de benazepril.
WO2007040511A1 (fr) * 2005-09-28 2007-04-12 Teva Pharmaceutical Industries Ltd. Combinaisons stables de bésylate d'amlodipine et d'hydrochlorure de bénazépril

Also Published As

Publication number Publication date
WO2008065485A2 (fr) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2008064351A3 (fr) (r)-n-stéréoisomères d'analogues 4,5-époxy-morphinanium saturé en position 7 et 8
WO2007098352A3 (fr) Pyridineamides substitués pouvant être employés en tant qu'inhibiteurs d'époxyde hydrolase soluble
WO2008005877A3 (fr) Inhibiteurs de c-kit et leurs utilisations
WO2006074951A3 (fr) Composition d'olanzapine ou de donepezil a desintegration orale
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
WO2007079139A3 (fr) Formes solides de n-[2,4-bis(1,1-diméthyléthyl)-5-hydroxyphényl]-1,4-dihydro-4-oxoquinoléine-3-carboxamide
WO2008063910A3 (fr) Procédé pour préparer des formes de dosage solides de compositions pharmaceutiques à plusieurs phases
WO2004105781A3 (fr) Compositions pharmaceutiques peptidiques stabilisees
HK1129581A1 (fr)
AU2003244632A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
AU2003244649A1 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2007122581A3 (fr) Compositions et kits utiles dans le traitement de maladies respiratoires
WO2007102127A3 (fr) Nouvelles amines
WO2007056625A3 (fr) Inhibiteurs de thienopyridine b-raf kinase
WO2008001325A3 (fr) Compositions phytothérapeutiques destinées au traitement de maladies de la cavité buccale
EA200900194A1 (ru) Новая противогрибковая композиция
WO2006129237A3 (fr) Nouveaux derives d'amide d'acide piperidine carboxylique
WO2008065485A3 (fr) Compositions pharmaceutiques stables composées d'un bloqueur des canaux calcium et d'un inhibiteur ace
WO2008088779A3 (fr) Formes solides de 5-azacytidine et procédés de préparation de ces dernières
TW200621773A (en) Bicyclononene derivatives
WO2008061108A3 (fr) Dérivés de phtalazine
WO2004113297A3 (fr) Derives de noyaux aza et utilisation de ceux-ci comme inhibiteurs de la recapture des neurotransmetteurs monoaminergiques
WO2007099509A3 (fr) NouveLLES aminEs primaires
WO2006021401A3 (fr) Derives de bicyclononene

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07825317

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07825317

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0717974

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090417